Geron Corporation (GERN) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

58/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

81

Deep Value

Momentum

54

Neutral

Sentiment

50

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Harout Semerjian
Listed since: Jul 31, 1996
Employees: 258

Market position

Volume: 4.43M; 0.35× average
Average volume: 12.72M; Average daily volume
Market cap: 975.11M USD
Beta: 0.59; Market reference 1

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score: -2.03
Piotroski F-score: 1 of 9

Earnings

EPS beat rate: 73%; 8 beats, 1 miss, 2 met estimates
Average EPS surprise: +9.33%; 11 comparable reports
Latest EPS result: -0.02; Estimate -0.01 · Miss by 125.23%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

GERN news

globenewswire.comAug 18, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase…

Read source

seekingalpha.comAug 18, 2026

Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis

Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. GERN's management did not increase its 2026 revenue guidance, but did suggest revenues were likely to reach the…

Read source

defenseworld.netAug 14, 2026

Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison

Geron (NASDAQ: GERN - Get Free Report) and Shattuck Labs (NASDAQ: STTK - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the…

Read source

seekingalpha.comAug 5, 2026

Geron Corporation (GERN) Q2 2026 Earnings Call Transcript

Read source

zacks.comAug 5, 2026

Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates

Geron (GERN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.

Read source

marketbeat.comAug 5, 2026

Geron Q2 Earnings Call Highlights

Geron NASDAQ: GERN reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic…

Read source